RNAscope® Technology is a cutting-edge multiplex nucleic acid in situ hybridization technology, based on ACD’s unique, patented probe design strategy which enables simultaneous signal amplification and background noise suppression. RNAscope Technology represents one of the most significant advances in ISH technology in over 40 years.
What is the value of Quantitative Molecular Detection and Morphological Context (MD & MC) in a single assay? What makes RNAscope unique?
RNAscope enables in situ detection of RNA biomarkers—filling a long standing gap in in situ molecular analysis.
RNAscope can complement IHC when antibodies are unavailable or have insufficient sensitivity or uncertain specificity. RNAscope is ideal for detecting RNAs for secreted proteins and non-coding RNA—a limitation of IHC.
Downstream of microarrays and NGS (e.g., RNA-seq), RNAscope is an ideal platform for translating new scientific advances into clinical applications due to the speed of RNAscope assay development and its superior sensitivity and specificity.
Other RNA biomarker analysis methods such as RT-PCR can provide quantitative, sensitive and specific measurements of RNA transcripts. However, the resulting quantitative gene expression information is without morphological and cellular context and only represents a “group average” of an admixture of heterogeneous populations of cells. RNAscope’s ability to provide gene expression at the single cell resolution coupled with morphological context is well-suited for RNA analysis in tissue diagnostics applications.